CAT

880.24

+1.69%↑

301.79

+0.28%↑

GEV.US

1,039.26

-0.58%↓

RTX

176.91

+0.22%↑

218.99

-0.21%↓

CAT

880.24

+1.69%↑

301.79

+0.28%↑

GEV.US

1,039.26

-0.58%↓

RTX

176.91

+0.22%↑

218.99

-0.21%↓

CAT

880.24

+1.69%↑

301.79

+0.28%↑

GEV.US

1,039.26

-0.58%↓

RTX

176.91

+0.22%↑

218.99

-0.21%↓

CAT

880.24

+1.69%↑

301.79

+0.28%↑

GEV.US

1,039.26

-0.58%↓

RTX

176.91

+0.22%↑

218.99

-0.21%↓

CAT

880.24

+1.69%↑

301.79

+0.28%↑

GEV.US

1,039.26

-0.58%↓

RTX

176.91

+0.22%↑

218.99

-0.21%↓

Home・Akcijų sąrašas・Ocugen Inc

Ocugen Inc

Atidarymo kaina

1.38 2.99

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1.35

Max

1.35

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-1.5M -19M
Pardavimai	1.7M 1.5M
Pelnas, tenkantis vienai akcijai	-0.06
Pelno marža	-1,250.946
Darbuotojai	116
EBITDA	-987K -17M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+763.43% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-07-31

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-173M 454M
Ankstesnė atidarymo kaina	-1.61
Ankstesnė uždarymo kaina	1.38

Ocugen Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-25 08:24; UTC

Pagrindinės rinkos jėgos

Įsigijimai, susijungimai, perėmimai

Uber's $11.6 Billion Takeover Approach Lifts Delivery Hero Shares

2026-05-25 21:22; UTC

Uždarbis

Disney's 'Mandalorian and Grogu' Conquers Memorial Day Weekend Box Office -- Barrons.com

2026-05-25 20:50; UTC

Rinkos pokalbiai

Uždarbis

Basic Materials Roundup: Market Talk

2026-05-25 16:20; UTC

Rinkos pokalbiai

Uždarbis

Basic Materials Roundup: Market Talk

2026-05-25 16:01; UTC

Rinkos pokalbiai

China's Crude Imports Pullback Helps Cap Price Upside -- Market Talk

2026-05-25 14:43; UTC

Rinkos pokalbiai

Oil Unlikely to Fall Significantly Until Hormuz Fully Reopens -- Market Talk

2026-05-25 14:15; UTC

Rinkos pokalbiai

Crude Futures Retreat As U.S.-Iran Progress Toward Deal -- Market Talk

2026-05-25 13:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2026-05-25 12:58; UTC

Rinkos pokalbiai

Over 60% of Albertans Indicate No Interest in Separation From Canada -- Market Talk

2026-05-25 12:56; UTC

Rinkos pokalbiai

Uždarbis

Canadian Earnings Lifted by Higher Commodity Prices in Latest Quarter -- Market Talk

2026-05-25 12:48; UTC

Rinkos pokalbiai

Interest-Rate Cuts Unlikely in 2026 Even if Middle East Conflict Ends -- Market Talk

2026-05-25 12:48; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-05-25 12:34; UTC

Rinkos pokalbiai

Dollar Extends Falls on U.S.-Iran Deal Prospects -- Market Talk

2026-05-25 12:10; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Delivery Hero's Assets Look Strategic -- Market Talk

2026-05-25 11:00; UTC

Rinkos pokalbiai

Euro, Sterling, Riskier Currencies Rise Versus Weaker Dollar -- Market Talk

2026-05-25 10:19; UTC

Rinkos pokalbiai

Swiss Franc Rises to Highest in More Than Two Months Vs Euro -- Market Talk

2026-05-25 10:05; UTC

Uždarbis

Tenaga Nasional: Well-Positioned to Navigate Global Geopolitical Uncertainties

2026-05-25 10:04; UTC

Uždarbis

Tenaga Nasional: Operational Performance to Remain Resilient in 2026

2026-05-25 10:03; UTC

Uždarbis

Tenaga Nasional: 1Q Operating Profit Rose on Higher Electricity Demand, Lower Fuel Prices

2026-05-25 10:02; UTC

Uždarbis

Tenaga Nasional: 1Q Rev Rose on Higher Electricity Sales

2026-05-25 10:01; UTC

Uždarbis

Tenaga Nasional 1Q Net Up 3.7% on Year

2026-05-25 10:00; UTC

Uždarbis

Tenaga Nasional 1Q Rev Up 6.6% on Year

2026-05-25 09:56; UTC

Uždarbis

Tenaga Nasional Malaysia 1st-Quarter 2026 Earnings Summary Table

2026-05-25 09:56; UTC

Uždarbis

Tenaga Nasional 1Q EPS MYR0.1883

2026-05-25 09:56; UTC

Uždarbis

Tenaga Nasional 1Q Rev MYR17.1B

2026-05-25 09:56; UTC

Uždarbis

Tenaga Nasional 1Q Net MYR1.1B

2026-05-25 09:38; UTC

Rinkos pokalbiai

U.S.-Iran Talks Lifted Sentiment But No Agreement Would Quickly Restore Normal Market Conditions -- Market Talk

2026-05-25 09:33; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-05-25 09:33; UTC

Rinkos pokalbiai

India's Gold Import Tax Raise Won't Curb Demand -- Market Talk

2026-05-25 08:55; UTC

Rinkos pokalbiai

European Energy Stocks Slide on Falling Oil Prices -- Market Talk

Akcijų palyginimas

Kainos pokytis

Ocugen Inc Prognozė

Kainos tikslas

By TipRanks

763.43% į viršų

12 mėnesių prognozė

Vidutinis 11.57 USD 763.43%

Aukščiausias 22 USD

Žemiausias 7 USD

Remiantis 7 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Ocugen Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

7 ratings

Pirkti

Laikyti

Parduoti

Remiantis 7 analitikų, pateikusių Ocugen Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.